Jiangsu Hanbon Science and Technology
688755
ZERUN CO., LTD
301636
SENXUAN
830946
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
CN Stock MarketDetailed Quotes
688167 Focuslight Technologies Inc.
- 68.74
- +1.44+2.14%
Market Closed May 16 15:00 CST
6.21BMarket Cap-32.58P/E (TTM)
70.19High67.17Low21.04KlotVolume67.17Open67.30Pre Close144.70MTurnover2.33%Turnover RatioLossP/E (Static)90.36MShares93.0052wk High2.95P/B6.21BFloat Cap39.9152wk Low80.76Limit Up90.36MShs Float231.35Historical High53.84Limit Down4.49%Amplitude39.91Historical Low0.31Dividend TTM68.77Avg Price9.48KlotAsk0.45%Div YieldTTM100Lot Size10.43KlotBid
Focuslight Technologies Inc. Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 23.75%169.52M | 10.49%620.02M | 19.17%458.15M | 29.85%311.22M | 17.38%136.99M | 1.69%561.17M | -3.67%384.47M | -9.09%239.68M | 5.60%116.71M | 15.98%551.86M |
| Operating revenue | 23.75%169.52M | 10.49%620.02M | 19.17%458.15M | 29.85%311.22M | 17.38%136.99M | 1.69%561.17M | -3.67%384.47M | -9.09%239.68M | 5.60%116.71M | 15.98%551.86M |
| Total operating cost | 30.15%206.11M | 51.89%700.34M | 47.94%503.4M | 49.87%334.89M | 47.69%158.36M | 5.78%461.1M | 13.78%340.27M | 15.57%223.45M | 16.04%107.22M | 7.92%435.89M |
| Operating cost | 21.86%112.92M | 47.28%445.75M | 53.05%318.08M | 51.46%211.45M | 42.25%92.67M | 19.91%302.65M | 17.19%207.83M | 18.67%139.61M | 29.69%65.14M | 15.98%252.4M |
| Operating tax surcharges | 2.79%885.14K | 14.64%5.67M | -2.43%2.94M | 3.89%2.06M | 39.57%861.11K | 80.85%4.94M | 94.52%3.02M | 95.20%1.98M | -30.05%616.96K | 0.60%2.73M |
| Operating expense | 10.49%12.62M | 27.61%42.92M | 31.89%34.27M | 33.33%21.61M | 49.06%11.42M | -3.11%33.63M | 8.56%25.98M | -1.13%16.21M | -17.95%7.66M | 2.56%34.71M |
| Administration expense | 61.50%36.1M | 34.46%111.03M | 2.39%78.84M | 0.49%49.1M | -8.21%22.36M | -15.47%82.57M | 33.53%76.99M | 38.80%48.86M | 45.60%24.35M | 38.81%97.69M |
| Financial expense | -157.06%-4.93M | 99.75%-102.27K | 90.53%-3.05M | 114.22%3.12M | 192.50%8.65M | -45.86%-41.3M | -80.24%-32.23M | -104.11%-21.96M | -29,581.51%-9.35M | -344.81%-28.31M |
| -Interest expense (Financial expense) | 17.36%3.4M | 279.63%12.93M | 520.16%8.72M | 673.16%7.9M | 524.40%2.89M | 247.83%3.4M | 90.52%1.41M | 50.22%1.02M | 10.32%463.32K | 89.18%978.87K |
| -Interest Income (Financial expense) | 45.37%-4.43M | 20.04%-28.17M | 7.45%-22.51M | -4.46%-16.07M | -1.89%-8.11M | -21.88%-35.23M | -12.50%-24.33M | -8.96%-15.38M | -151.46%-7.96M | -10,164.67%-28.9M |
| Research and development | 116.47%48.51M | 20.96%95.08M | 23.27%72.32M | 22.69%47.54M | 19.23%22.41M | 2.51%78.6M | 3.94%58.67M | 14.49%38.75M | 23.71%18.79M | 13.11%76.67M |
| Credit Impairment Loss | 150.33%4.63M | 6.44%-8.53M | 96.94%-346.02K | 94.11%-68.86K | 3,181.17%1.85M | -223.30%-9.12M | -55.67%-11.33M | 80.84%-1.17M | 105.95%56.33K | 64.09%-2.82M |
| Asset Impairment Loss | -3.98%-6.2M | -388.13%-121.84M | -82.10%-23.76M | -62.56%-17.3M | -29.83%-5.96M | -43.40%-24.96M | 6.29%-13.05M | -7.65%-10.64M | 3.06%-4.59M | -105.68%-17.41M |
| Other net revenue | ||||||||||
| Fair value change income | -57.46%233.51K | -86.41%1.79M | -86.45%1.69M | -88.81%1.15M | -89.54%548.91K | -41.29%13.17M | -41.17%12.44M | -27.53%10.26M | 110.21%5.25M | 683.67%22.43M |
| Invest income | 17.11%-94.18K | -46.98%-835.72K | -17.47%-511.33K | -465.87%-464.49K | ---113.62K | ---568.61K | ---435.27K | ---82.08K | ---- | ---- |
| -Including: Investment income associates | 17.11%-94.18K | -861.41%-799.49K | -1,439.56%-492.09K | ---445.25K | ---113.62K | ---83.16K | ---31.96K | ---- | ---- | ---- |
| Asset deal income | -73.00%22.14K | 101.98%66.35K | 181.76%194.11K | 652.63%71.71K | 147,835.20%82.01K | -2,494.71%-3.35M | -29.08%68.89K | -123.05%-12.98K | -100.11%-55.51 | 186.02%139.8K |
| Other revenue | -73.64%1.22M | 18.35%18.85M | 29.81%10.33M | 63.79%8.27M | 17.23%4.61M | -18.83%15.93M | -46.34%7.96M | -34.44%5.05M | 32.81%3.93M | 6.07%19.62M |
| Operating profit | -80.68%-36.77M | -309.28%-190.82M | -244.62%-57.65M | -263.05%-32.02M | -244.01%-20.35M | -33.90%91.18M | -65.32%39.86M | -74.24%19.64M | -21.26%14.13M | 79.68%137.94M |
| Add:Non operating Income | 111.01%872.55K | -88.30%632.19K | -90.22%441.34K | -90.51%423.02K | -55.89%413.51K | -41.49%5.4M | -53.01%4.51M | -19.36%4.46M | -80.70%937.5K | 3,360.39%9.24M |
| Less:Non operating expense | 394.59%140.38K | 244.31%1.63M | -87.88%95.06K | -89.80%75.17K | -59.43%28.38K | 4.01%473.12K | 78.70%784.6K | 268.45%737.27K | -34.61%69.96K | 24.89%454.86K |
| Total profit | -80.50%-36.04M | -299.58%-191.81M | -231.46%-57.31M | -235.60%-31.67M | -233.11%-19.97M | -34.49%96.11M | -64.88%43.59M | -71.37%23.35M | -33.92%15M | 91.36%146.72M |
| Less:Income tax cost | -8.19%-4.09M | -403.81%-16.9M | -982.65%-5.52M | -18.40%-3.55M | -1,941.91%-3.78M | -72.70%5.56M | -96.50%625.23K | -124.13%-3M | -104.96%-185.02K | 72.82%20.38M |
| Net profit | -97.38%-31.95M | -293.17%-174.91M | -220.53%-51.79M | -206.71%-28.12M | -206.61%-16.19M | -28.33%90.55M | -59.57%42.97M | -61.89%26.35M | -19.95%15.19M | 94.72%126.34M |
| Net profit from continuing operation | -97.38%-31.95M | -293.17%-174.91M | -220.53%-51.79M | -206.71%-28.12M | -206.61%-16.19M | -28.33%90.55M | -59.57%42.97M | -61.89%26.35M | -19.95%15.19M | 94.72%126.34M |
| Less:Minority Profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 73.75%-756.26K |
| Net profit of parent company owners | -97.38%-31.95M | -293.17%-174.91M | -220.53%-51.79M | -206.71%-28.12M | -206.61%-16.19M | -28.76%90.55M | -59.86%42.97M | -61.90%26.35M | -24.65%15.19M | 87.56%127.09M |
| Earning per share | ||||||||||
| Basic earning per share | -94.44%-0.35 | -293.07%-1.95 | -220.83%-0.58 | -206.90%-0.31 | -205.88%-0.18 | -28.37%1.01 | -59.66%0.48 | -62.34%0.29 | -22.73%0.17 | 41.00%1.41 |
| Diluted earning per share | -94.44%-0.35 | -293.07%-1.95 | -220.83%-0.58 | -206.90%-0.31 | -205.88%-0.18 | -28.37%1.01 | -59.66%0.48 | -62.34%0.29 | -22.73%0.17 | 41.00%1.41 |
| Other composite income | 252.04%15.91M | -763.51%-45.76M | -170.72%-2.21M | -435.11%-24.96M | -1,047.37%-10.47M | 48.61%6.9M | 284.43%3.12M | 438.41%7.45M | 162.62%1.1M | 147.14%4.64M |
| Other composite income of parent company owners | 252.04%15.91M | -763.51%-45.76M | -170.72%-2.21M | -435.11%-24.96M | -1,047.37%-10.47M | 66.11%6.9M | 243.08%3.12M | 454.85%7.45M | 164.89%1.1M | 144.24%4.15M |
| Other composite income of minority owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 206.57%488.97K |
| Total composite income | 39.81%-16.04M | -326.46%-220.67M | -217.16%-53.99M | -257.04%-53.08M | -263.63%-26.66M | -25.60%97.44M | -55.93%46.09M | -49.51%33.8M | -5.32%16.29M | 137.99%130.98M |
| Total composite income of parent company owners | 39.81%-16.04M | -326.46%-220.67M | -217.16%-53.99M | -257.04%-53.08M | -263.63%-26.66M | -25.76%97.44M | -56.05%46.09M | -49.60%33.8M | -11.71%16.29M | 124.83%131.25M |
| Total composite income of minority owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 92.00%-267.28K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.